智通财经APP讯,兆科眼科-B(06622)发布公告,于2026年7月13日,公司的创新药YUVEZZI™(2.75% 卡巴胆硷及0.1%酒石酸溴莫尼丁滴眼液)已获澳门特别行政区政府药物监督管理局批准用于治疗老花眼。
公司正积极争取YUVEZZI™加入“港澳药械通”计划,旨在促进该产品尽早于大湾区实现临床使用。公司致力为创新的老花眼治疗方案提供高效准入途径,尽快让更多患者受惠。
智通财经APP讯,兆科眼科-B(06622)发布公告,于2026年7月13日,公司的创新药YUVEZZI™(2.75% 卡巴胆硷及0.1%酒石酸溴莫尼丁滴眼液)已获澳门特别行政区政府药物监督管理局批准用于治疗老花眼。
公司正积极争取YUVEZZI™加入“港澳药械通”计划,旨在促进该产品尽早于大湾区实现临床使用。公司致力为创新的老花眼治疗方案提供高效准入途径,尽快让更多患者受惠。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.